Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol.
Pediatr Blood Cancer
; 63(7): 1290-2, 2016 07.
Article
em En
| MEDLINE
| ID: mdl-27100060
ABSTRACT
A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months. There was only slight reduction in tumor mass, but measurement of propranolol levels showed extremely low plasma concentrations. The propranolol dose was progressively increased to 3.5 mg/kg/day, leading to a substantial increase in plasma levels associated with clinically relevant tumor reduction. This case highlights the importance of relating propranolol dose to its plasma concentration before considering the treatment ineffective for this vascular tumor.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Propranolol
/
Sarcoma de Kaposi
/
Resistencia a Medicamentos Antineoplásicos
/
Síndrome de Kasabach-Merritt
/
Hemangioendotelioma
/
Doenças do Recém-Nascido
Limite:
Humans
/
Male
/
Newborn
Idioma:
En
Revista:
Pediatr Blood Cancer
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Itália